IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Active Pharmaceutical Ingredient (API) product 'Fenofibrate - Process II'. This is in addition to the existing CEP held by the company for 'Fenofibrate'. The new CEP strengthens the company's regulatory portfolio and supports its ability to cater to regulated markets for Fenofibrate.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the closure of its trading window for all designated persons and their immediate relatives, effective from October 1, 2026, until the expiry of 48 hours after the declaration of the financial results for the quarter and half year ended September 30, 2026.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has received REACH certification/registration for its product 'Triacetin' under the EU-REACH framework, enabling the company to export the product across all European Union countries.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced a schedule for an analyst/institutional investor meeting on 29th September 2026, where the management will discuss past financial results and publicly available information.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced a schedule for an analyst/institutional investor meeting on September 28, 2026, where the company's management will discuss past financial results and publicly available information.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the voting results and scrutinizer's report for its 39th Annual General Meeting, which was held on September 2, 2026. The meeting was attended by 87 public shareholders through video conferencing, and 5 promoter shareholders. Three resolutions were passed, including the adoption of the standalone and consolidated audited financial description of the company for the financial year ended March 31, 2026.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd held its 39th Annual General Meeting (AGM) on September 2, 2026, through video conferencing. The meeting was attended by the Chairman, Mr. Rajender Mohan Malla, and the Company Secretary, Mr. Abhay Raj Singh. The AGM approved the standalone and consolidated audited financial statements for the financial year ended March 31, 2026. The meeting also ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The voting results were announced, and the reports of the statutory auditors and secretarial auditors did not contain any qualifications or comments.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced a schedule for an analyst/institutional investor meeting on 3rd September 2026, organized by Phillip Capital (India) Private Limited. The meeting will be held in person and will focus on past financial results and publicly available information. No unpublished price-sensitive information will be disclosed.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has reported a strong Q1 FY27 performance, driven by healthy demand across key products, improved capacity utilization, favorable product mix, and operational efficiency. The company has made progress in diversifying its API portfolio beyond ibuprofen, with non-ibu products contributing 43% of pharmaceutical revenue in Q1 FY27, up from 36% in Q1 FY26. The company's international business also strengthened during the quarter, with exports increasing to 28.5% of revenue.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the submission of newspaper publication regarding a special window for transfer-cum-dematerialisation of physical shares, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the audio recording of its Analysts/Investors Call pertaining to the Financial Results Q1- FY2027, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has released its Q1 FY27 investor presentation, highlighting a 37.1% YoY increase in revenue from operations to ₹756.3 Cr, with PAT and EBITDA margins improving to 8.4% and 14.6% respectively. The company's Q1 FY27 standalone performance highlights include a 60.7% YoY increase in EBITDA to ₹111.7 Cr, and a 37.1% YoY increase in revenue from operations to ₹756.3 Cr.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced the notice of its 39th Annual General Meeting (AGM) and the Integrated Annual Report for the financial year 2025-26. The AGM will be held on September 2, 2026, through video conferencing. The annual report is available on the company's website and on the websites of the stock exchanges where the company's securities are listed.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has submitted the newspaper publication of unaudited financial results for the quarter ended 30th June 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd reported its Q1 FY27 results, with revenue from operations increasing 37.1% YoY to ₹756.3 Cr, EBITDA rising 60.7% YoY to ₹111.7 Cr, and PAT increasing 89.9% YoY to ₹64.5 Cr. The company's Pharmaceuticals business saw a 43% YoY revenue growth and 72% YoY EBIT growth, driven by improved capacity utilisation, favourable product mix, and operational efficiencies.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with revenue from operations at ₹756.26 crore and profit before exceptional items and tax at ₹86.77 crore.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June 2026, with a profit before exceptional items and tax of ₹86.77 crore, a decline from ₹70.83 crore in the previous quarter.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd has published a notice in newspapers regarding the 39th Annual General Meeting (AGM) and e-voting information. The company has sent the AGM notice and integrated annual report to members whose email addresses are registered with the company. The documents are also available on the company's website and on the website of Central Depository Services (India) Ltd. The AGM notice is also available on the website of the Stock Exchange of India Ltd. The company has informed members that the ordinary and special businesses will be transacted through voting by electronic means and there will be no physical meeting. The remote e-voting period will commence on 30th August 2026 at 9:00 AM.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd is organizing an analyst/investor conference call on August 13th to discuss Q1 FY27 financial performance.

IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, as per Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.